|Bid||2.1300 x 1800|
|Ask||2.1800 x 1400|
|Day's Range||2.0800 - 2.2200|
|52 Week Range||1.8200 - 4.4500|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Johnson & Johnson (NYSE: JNJ) hasn't been a major player in the vaccine market in the past, but that's changing. It's now seeking to develop a flu vaccine through a recent deal with small biotech Cidara Therapeutics (NASDAQ: CDTX). In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J could become a big winner in the flu vaccine market.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021. Presentation Information:Date:Wednesday, April 14, 2021Time:1:30 PM ETWebcast: A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com. About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) firstname.lastname@example.org MEDIA CONTACT:Patrick BurseyLifeSci Communications(203) email@example.com
Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.